Some of you may have missed the testimony by Office of Inspector General (OIG) Chief Counsel Lewis Morris at a hearing before the U.S. Senate Special Committee on Aging just before the congressional recess. During his testimony, Morris recounted some of the big name and widely publicized cases involving inappropriate conduct by industry in interactions with health care professionals related to the provision of continuing medical education (CME). The most interesting part of his testimony, however, came when Morris offered some recommendations for industry to best ensure that CME "serves a bona fide educational purpose." In acknowledging that the elimination of industry sponsorship for CME altogether would threaten the availability of CME, Morris reviewed OIG recommendations from the 2003 Compliance Program Guidance for Pharmaceutical Manufacturers, including (1) the separation of grant-making functions from sales and marketing, (2) the establishment of objective criteria for making educational grants to CME providers and (3) the elimination of any control over speakers or content of CME activities. Morris went on to promote the establishment of independent CME grant organizations that could accept donations from industry and distribute funds to CME providers based on the direction of an independent board of experts. Additionally, Morris said that safeguards for industry could include establishing broad educational categories for the allocation of donations to minimize the risk of commercial influence associated with grant awards. However, his idea of "intermediary" grant-making organizations sponsored broadly by industry or by segments of the industry is not likely to catch on under the existing industry codes on interactions with health care professionals and competitive marketplace, which promotes direct rather than diffused support for CME events. Were the Accreditation Council for Continuing Medical Education (ACCME) to require such an approach for commercial support of CME, such a proposal would likely gain traction among the industry. As it stands today, the Pharmaceutical Research and Manufacturers of America (PhRMA) permits, in its Code on Interactions with Healthcare Professionals, direct industry support for CME where CME grant-making is separate from sales and marketing functions and ACCME standards for commercial support are observed. The device industry's Advanced Medical Technology Association is less restrictive of industry involvement in CME and permits company recommendations for CME faculty (so long as the CME sponsor makes final selections) and sales and marketing input on the suitability of a grant or donation recipients (so long as sales is not given control or undue influence over the decision).